[Comment] Adjuvant zoledronic acid to treat breast cancer: not for all

Bisphosphonates have been extensively studied in the adjuvant setting as a host-directed therapy to reduce the risk of breast-cancer relapse. The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) patient-level meta-analysis of adjuvant bisphosphonates, which included 18  776 women with breast cancer, showed a reduction in breast-cancer-associated death among postmenopausal women (hazard ratio [HR] 0·82, 95% CI 0·73–0·93). This outcome was mainly due to the reduction in bone recurrence. Thus, several guidelines have included zoledronic acid and clodronic acid as adjuvant treatments for breast cancer in postmenopausal women.

Source: The Lancet Oncology - October 13, 2017 Category: Cancer & Oncology Authors: Lu ís Costa, Arlindo R Ferreira Tags: Comment Source Type: research